VALTOCO

Peak

diazepam

NDANASALSPRAY
Approved
Jan 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
4

Mechanism of Action

Pharmacologic Class:

Benzodiazepine

Clinical Trials (4)

NCT07020988Phase 1Completed

A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy Participants

Started Jun 2025
55 enrolled
Healthy Participants
NCT05076838Phase 1/2Completed

Pharmacokinetics Study of VALTOCO® in Pediatric Subjects With Epilepsy

Started Nov 2021
35 enrolled
Epilepsy
NCT01364558Phase 1Completed

A Study of Diazepam After Intranasal and Intravenous Administration to Healthy Volunteers

Started Feb 2011
24 enrolled
Epilepsy
NCT00319501Phase 3Completed

Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures.

Started Jan 2006
234 enrolled
SeizuresEpilepsies, PartialEpilepsy, Complex Partial+2 more

Loss of Exclusivity

LOE Date
Oct 16, 2032
80 months away
Patent Expiry
Oct 16, 2032
Exclusivity Expiry
Apr 15, 2028

Patent Records (5)

Patent #ExpiryTypeUse Code
8895546
Mar 27, 2029
Product
11793786
Mar 27, 2029
Product
12268664
Mar 27, 2029
Product
11241414
Mar 27, 2029
Product
12521400
Mar 27, 2029
Product